pSivida (PSDV) PT Set at $5.00 by B. Riley
pSivida (NASDAQ:PSDV) has been assigned a $5.00 price target by equities research analysts at B. Riley in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the stock. B. Riley’s price objective points to a potential upside of 342.48% from the company’s current price.
Several other research analysts also recently commented on PSDV. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of pSivida in a report on Tuesday, September 12th. Laidlaw assumed coverage on pSivida in a report on Wednesday, November 8th. They set a “buy” rating and a $5.00 target price on the stock. ValuEngine lowered pSivida from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Northland Securities reissued a “buy” rating and issued a $10.00 price objective on shares of pSivida in a research report on Monday, December 11th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. pSivida has a consensus rating of “Buy” and a consensus price target of $7.57.
Shares of pSivida (PSDV) traded up $0.07 on Friday, reaching $1.13. The company’s stock had a trading volume of 888,161 shares, compared to its average volume of 510,891. pSivida has a 52-week low of $1.02 and a 52-week high of $2.45.
An institutional investor recently raised its position in pSivida stock. Renaissance Technologies LLC lifted its holdings in pSivida Corp. (NASDAQ:PSDV) by 6.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 963,043 shares of the company’s stock after acquiring an additional 56,043 shares during the period. Renaissance Technologies LLC owned approximately 2.82% of pSivida worth $1,656,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 9.70% of the company’s stock.
pSivida Company Profile
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.